Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Alibaba Health ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里 健康 信息 技術 有限公司 ( Incorporated in Bermuda with limited liability ) ( Stock code : 00241 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30 , 2021 The board ( the " Board " ) of directors ( the “ Directors " ) of Alibaba Health Information Technology Limited ( the “ Company ” or “ Alibaba Health ” ) is pleased to announce the unaudited interim results of the Company and its subsidiaries ( collectively referred to as the " Group " ) for the six months ended September 30 , 2021 ( the " Reporting Period ” ) together with comparative figures for the corresponding period of the preceding year . The interim condensed consolidated financial statements have been reviewed by the audit committee of the Company . HIGHLIGHTS During the Reporting Period , the Group recorded revenue of approximately RMB9,357.7 million , representing a year - on - year growth of 30.7 % , and gross profit of approximately RMB1,870.8 million . The continued rapid growth in revenue was attributable to our strategy of focusing on drugs sales and services through pharmaceutical direct sales business and diversifying supply of pharmaceutical and healthcare products by introducing merchants to our e - commerce platforms . Revenue from drugs generated from the pharmaceutical direct sales business under the brand of " Alibaba Health ” accounted for 64 % of the revenue of the business , and revenue from the prescription drug business increased by 127.3 % year - on - year . -1-